Prosecution Insights
Last updated: November 04, 2026
Application No. 18/930,942

DERIVATIVES OF 5-HYDROXYLATED POLYMETHOXYFLAVONES WITH ENHANCED BIOAVAILABILITY FOR ORAL DELIVERY AND COMPOSITIONS THEREOF

Non-Final OA §103
Filed
Oct 29, 2024
Examiner
SOROUSH, LAYLA
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Deepsense Biotechnologies Inc.
OA Round
1 (Non-Final)
40%
Grant Probability
Moderate
1-2
OA Rounds
1y 9m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allowance Rate
361 granted / 893 resolved
-19.6% vs TC avg
Strong +44% interview lift
Without
With
+43.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
60 currently pending
Career history
952
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
50.4%
+10.4% vs TC avg
§102
11.1%
-28.9% vs TC avg
§112
13.3%
-26.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 893 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first- inventor-to-file provisions of the AIA . Application Priority This application was filed on 10/29/2024. Status of the Claims Claims 1-18, are currently pending and are examined on the merits herein. Information Disclosure Statement No information disclosure statement(s) (IDS) filed. The rejection is as below: Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-10 are rejected under 35 U.S.C. 103 as being unpatentable over Guthrie et al. (WO2007002897 A2). Guthrie et al. teaches a pharmaceutical ingredient comprising a combination of polymethoxyflavones and phospholipids, wherein the combination of the polymethoxyflavones and the phospholipids is in the form of a matrix. (claim 1) Examples of naturally occurring polymethoxyflavones include, but are not limited to, nobiletin, tangeretin, 5-desmethylnobiletin (5-Hydroxy-6,7,8,3′,4′-pentamethoxyflavone), tetramethylscutellarein, and sinensetin. Phospholipids have many desirable health benefits. They are an excellent source of choline, inositol, and serine which prevent accumulation of fat in the liver, control nerve impulses, aid in memory function, and integrate electrical activity across the brain zones. They are also very high in linoleic acid, an essential fatty acid. Common types of phospholipids are phosphatidyl-choline (PC), -inositol (PI), -serine (PS) and -ethanolamine (PE). However, the term phospholipid, as used herein may comprise any species of lecithin including but not limited to modified, natural, synthetic, bleached, unbleached, powdered, granular, liquid, glycero-, lyso-, polyenyl PC, PPC components, and any enriched phospholipid compounds (reads on glycerophospholipid which broadly reads on a glyceride). While Guthrie teaches polymethoxyflavones and the phospholipids in the form of a matrix, the reference fails to specify the lipid carrier on R5; nor does the reference specify the LogP value, or solubility, or oral bioavailability parameters of claims 3-4 and 10. It would have been obvious to one of ordinary skill in the art at the time of filing to use the polymethoxyflavones with the phospholipids. The motivation to use the polymethoxyflavones with the phospholipids is because Guthrie teaches polymethoxyflavones and the phospholipids in the form of a matrix and a major advantage to a lecithin phospholipid carrier is that it is known to increase the bioavailability of other lipid ingredients. A skilled artisan would have reasonable expectation of successfully achieving increase bioavailability. It is the examiner's position that, obviously, the composition advanced by '897 has the LogP value, or solubility, or oral bioavailability parameters consistent with those enumerated in the instant claims set. Since the essential elements of the '897 composition are similar to the instant compositions (that is, comprising polymethoxyflavones and the phospholipids in the form of a matrix), the composition would obviously have the same physiochemical properties as the compositions set forth in the instant application. As such, it is the examiner's position that the composition advanced by '897 renders obvious the compositions enumerated in the instant claim set. Claims 11-16 and 18 are rejected under 35 U.S.C. 103 as being unpatentable over Guthrie et al. (WO2007002897 A2), as applied to claims 1-10 above, and further in view Miljkovic (WO 9938509 A1). Guthrie et al. is as discussed above. Guthrie et al. fails to teach a hydrophilic carrier, a solvent is an ester of glycerol, glycol, or fatty alcohol, and fatty acid having an HLB value of less than 5, bioavailability enhancer including ether of diethylene glycol. Miljkovic teaches an isoflavanoid formulation comprising amphiphilic carrier comprises a glyceride and solvents comprising glycerol, polyglycerol, ethyl and diethyl ether of diethylene glycol. Amphiphilic carriers are particularly contemplated, including Gelucire-series, Labrafil, Labrasol, or Lauroglycol (all manufactured and distributed by Gattefosse Corporation, Saint Priest, France), PEG-mono-oleate, PEG-di-oleate, PEG-mono- laurate and di-laurate, Lecithin, Polysorbate 80, etc. It would have been obvious to one of ordinary skill in the art at the time of filing to incorporate a hydrophilic carrier, a solvent is an ester of glycerol, glycol, or fatty alcohol, and fatty acid having an HLB value of less than 5, bioavailability enhancer including oleyl alcohol, ether of diethylene glycol. The motivation to incorporate a hydrophilic carrier, a solvent is an ester of glycerol, glycol, or fatty alcohol, and fatty acid having an HLB value of less than 5, bioavailability enhancer including oleyl alcohol, ether of diethylene glycol is because Miljkovic teaches preferred amphiphilic carriers are generally those that have GRAS status, and that can both solubilize isoflavanoids and microemulsify them at a later stage when the isoflavanoid solution comes into a contact with a complex water phase (such as one found in human gastro-intestinal tract). Usually, amphiphilic ingredients that satisfy these requirements have HLB (hydrophilic to lipophilic balance) values of 2-20. Further, solvents are used in oral formulations, referred solvents are relatively non-toxic. A skilled artisan would have reasonable expectation of successfully achieving solubilization. It is the examiner's position that, obviously, the composition having the same solvents, will promote lymphatic uptake as claimed. Claim 17 is rejected under 35 U.S.C. 103 as being unpatentable over Guthrie et al. (WO2007002897 A2) in view of Miljkovic (WO 9938509 A1), as applied to claims 1-16 and 18 above, and further in view of Fatmi et al. (US 20150118298 A1). Guthrie et al. and Miljkovic are as discussed above. Guthrie et al. and Miljkovic fail to teach a bioavailability enhancer including oleyl alcohol. Fatmi et al. is solely used for its teaching that emulsifying or solubilizing agents include acacia, cholesterol, diethanolamine, glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, monoethanolamines, oleic acids, oleyl alcohols. It would have been obvious to one of ordinary skill in the art at the time of filing to incorporate bioavailability enhancer including oleyl alcohol. The motivation to incorporate a bioavailability enhancer including oleyl alcohol is because Fatmi teaches oleyl alcohols act as emulsifying or solubilizing agents. A skilled artisan would have reasonable expectation of successfully achieving emulsification/solubilization. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA SOROUSH whose telephone number is (571)272-5008. The examiner can normally be reached on Monday thru Friday; 8:30 AM to 5:00 PM PST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Henry Alstrum-Acevedo, can be reached on (571)272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAYLA SOROUSH/ Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Oct 29, 2024
Application Filed
Sep 10, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12751955
FORMULATION FOR ORAL ADMINISTRATION, COMPRISING TRIAZINE DERIVATIVE
3y 1m to grant Granted Oct 06, 2026
Patent 12752009
IONIC LIQUIDS FOR TRANSDERMAL DRUG DELIVERY
3y 0m to grant Granted Oct 06, 2026
Patent 12751947
ORAL LIQUID FORMULATION OF APIXABAN
1y 8m to grant Granted Oct 06, 2026
Patent 12746286
LONG-ACTING ROPIVACAINE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
4y 0m to grant Granted Sep 29, 2026
Patent 12697318
ANTI-INFLAMMATORY AGENT CONTAINING RARE FATTY ACID
5y 8m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
40%
Grant Probability
84%
With Interview (+43.6%)
3y 9m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 893 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month